Tempest Therapeutics Inc TPST.OQ TPST.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of $3.29 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tempest Therapeutics Inc is $65.00, above its last closing price of $6.99.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -3.25 | -3.28 | -4.03 | Missed | -23 |
Sep. 30 2024 | -4.56 | -4.71 | -5.33 | Missed | -13.3 |
Jun. 30 2024 | -5.78 | -5.24 | -5.46 | Missed | -4.2 |
Mar. 31 2024 | -4.98 | -4.86 | -4.68 | Beat | 3.8 |
Dec. 31 2023 | -4.81 | -5.02 | -4.94 | Beat | 1.5 |
Sep. 30 2023 | -7.25 | -7.45 | -6.24 | Beat | 16.2 |
Jun. 30 2023 | -7.15 | -6.73 | -7.02 | Missed | -4.3 |
Mar. 31 2023 | -8.42 | -8.35 | -7.15 | Beat | 14.4 |
This summary was machine generated May 5 at 11:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。